Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 19

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 15
Chunk 19
---
 may become inadequate because of changes in conditions
and that the degree of compliance with the policies or procedures may deteriorate.

Our management has assessed
the effectiveness of internal control over financial reporting as of December 31, 2024 based on the Internal Control - Integrated
Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) 2013.

Based on this assessment, o ur
management concluded that our internal control over financial reporting was effective as of December 31, 2024.

  Attestation Report of the Registered Public Accounting Firm  

This annual report does not
include an attestation report of our registered public accounting firm we are a non-accelerated filer.

  114  

  Table of Contents  

  Changes in Internal Control Over Financing Reporting  
 ────────────────────────────────────────────────────────

We regularly review our system
of internal control over financial reporting to ensure we maintain an effective internal control environment. Other than the changes discussed
herein, there were no changes in our internal control over financial reporting that occurred during the fiscal year ended December 31,
2024 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

  ITEM 16A.      AUDIT COMMITTEE FINANCIAL EXPERT.  
 ────────────────────────────────────────────────────

The Audit Committee consists
of three members: Simon Turton (Chairman), Stephen Parker and Ann Merchant. The Board of Directors has determined that Messrs. Turton
and Parker and Ms. Merchant are independent under Rule 10A-3 of the Exchange Act and the applicable rules of NASDAQ and that Dr. Turton
qualifies as an “audit committee financial expert” as defined under in Item 16A of Form 20-F.

  ITEM 16B.      CODE OF ETHICS.  
 ──────────────────────────────────

We have adopted a Code of
Ethics and Business Conduct, or Code of Ethics, which is applicable to all of our employees, officers and directors and is available on
our website at http://www. biodexapharma. com/investors/corporate-governance. The Code of Ethics provides that our directors and officers
are expected to avoid any action, position or interest that conflicts with the interests of the Group or gives the appearance of a conflict.
Our directors and officers have an obligation under the Code of Ethics to advance our interests when the opportunity to do so arises